ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vepdegestrant

Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.

Its studies are mostly in Breast Neoplasms, led by 3 companies.

Drug pageVepdegestrant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 16, 202220 company-led studies, 6 open or runningNext primary completion: Dec 4, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer176 open or runningphase 3since Nov 16, 2022Jul 14, 2022Dec 4, 2026phase 1 · NCT07231991
Arvinas Estrogen Receptorits history only20 open or runningphase 2since Aug 27, 2019Aug 27, 2019none ahead
Arvinasits history only10 open or runningphase 2since Sep 7, 2022Sep 7, 2022none ahead

Also a collaborator on its studies: Carrick Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 3 earlier studies, Jul 14, 2022 to Sep 8, 2022.

  1. Jul 21, 2022Named vepdegestrantINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARV-471
  2. Oct 5, 2022Phase 2 study in Breast NeoplasmsNCT05573555 · 20 enrolled · United States, Canada, Italy and more
  3. Nov 16, 2022Phase 3 study in Breast NeoplasmsNCT05654623 · 624 enrolled · United States, Argentina, Australia and more
  4. Dec 7, 20222 phase 1 studies in HealthyNCT05652660, NCT05673889
  5. Jan 17, 2023Phase 1 study in Breast NeoplasmsNCT05732428 · 9 enrolled · China
  6. May 25, 2023Phase 3 study in Breast NeoplasmsNCT05909397 · 59 enrolled · United States, Australia, Brazil and more
  7. Jun 8, 2023Phase 1 study in HealthyNCT05930925 · 12 enrolled · United States
  8. Aug 15, 2023Phase 1 study in Healthy ParticipantsNCT06005688 · 12 enrolled · Belgium
  9. Oct 16, 2023Phase 2 study in Breast NeoplasmsNCT06125522 · 11 enrolled · United States, Belgium, France and more
  10. Dec 13, 2023Phase 2 study in Breast NeoplasmsNCT06206837 · 71 enrolled · United States, Belgium, Canada and more
  11. Feb 5, 20242 phase 1 studiesNCT06256510, NCT06275841
  12. Mar 28, 2025Phase 1 study in Healthy ParticipantsNCT06911788 · 10 enrolled · Netherlands
  13. Nov 13, 2025Phase 1 study in Healthy ParticipantsNCT07231991 · 24 planned · United States
  14. Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT05573555 · “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to…”
  15. Oct 27, 2026Phase 2 study terminatedStudy stoppedNCT06125522 · “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to …”

Ahead

  1. Dec 4, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07231991
  2. Dec 30, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05909397
  3. Mar 24, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05548127

TargetBeta

ESR1 →read by rule
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 17 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07231991Healthy Participants · United States1RecruitingDec 4, 202624
NCT06911788Healthy Participants · Netherlands1CompletedMay 23, 202510
NCT06275841Healthy · United States1CompletedMay 3, 202412
NCT06256510Healthy Participants · Belgium1CompletedApr 16, 202415
NCT06206837Breast Neoplasms · United States, Belgium, Canada and more2Active, not recruitingSep 5, 202571
NCT06125522Breast Neoplasms · United States, Belgium, France and more2TerminatedSep 10, 202611
NCT06005688Healthy Participants · Belgium1CompletedOct 11, 202312
NCT05930925Healthy · United States1CompletedJul 27, 202312
NCT05909397Breast Neoplasms · United States, Australia, Brazil and more3Active, not recruitingDec 30, 202659
NCT05732428Breast Neoplasms · China1CompletedMar 29, 20249
NCT05673889Healthy · Belgium1CompletedMar 15, 202324
NCT05652660Healthy · United States1CompletedFeb 9, 202312
NCT05654623Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJan 31, 2025624
NCT05573555Breast Neoplasms · United States, Canada, Italy and more2TerminatedOct 6, 202620
NCT05538312Healthy · Belgium1CompletedApr 24, 202312
NCT05548127Breast Neoplasms · United States, Canada, Italy and more2Active, not recruitingMar 24, 202737
NCT05463952Breast Neoplasms · Japan1Active, not recruitingMay 4, 20236

How it is read

Names in the registry

  • “ARV-471”, 7 entries
  • “vepdegestrant”, 6 entries
  • “Vepdegestrant”, 4 entries
  • “[phenyl-14C]ARV-471”, 1 entry
  • “[oxoisoindolin-14C]ARV-471”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.